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Abstract: The Liqui-Mass technology (also known as Liqui-Pellet technology) has shown promising
results in terms of enhancing the drug release rate of water insoluble drugs in a simplistic approach.
However, there is no current study on sustained-release formulation using the Liqui-Mass technology.
In this study, an attempt was made to produce a sustained-release Liqui-Tablet for the first time using
a matrix-based approach. The non-volatile co-solvent used in the investigation included Tween 80,
Tween 20 and Kolliphor EL. The production of sustained-release propranolol hydrochloride Liqui-
Tablet was successful, and data from the saturation solubility test and dissolution test did not show
much difference among the mentioned non-volatile co-solvent. The best Liqui-Tablet formulation
took 24 h for drug release to reach at around 100%. There seemed to be a synergistic retarding drug
release effect when a non-volatile co-solvent and Eudragit RS PO were used together. The increase of
Eudragit RS PO concentration increased the retardant effect. Kinetic drug release analysis suggests
that the best formulation followed the Higuchi model. The flowability of pre-compressed Liqui-Tablet
pellets had no issues and its size distribution was narrow. Liqui-Tablet was generally robust and
most formulations passed the friability test. The study revealed that Liqui-Mass technology can be
employed to sustain drug release.
Keywords: liqui-tablet; liqui-mass technology; liqui-pellet technology; sustained release; eudragit rs po;
kinetic model; matrix pellet
1. Introduction
Liqui-Mass technology, or sometimes referred to as Liqui-Pellet technology, is a re-
cently developed oral drug delivery system, which was first filed for a patent in 2018
and published internationally in 2020 [1]. It was developed in response to bringing the
concepts from liquisolid technology into a commercially feasible direction. Experimental
data in terms of enhanced dissolution rate and manufacturability have been shown to
be very promising [2–6]. The idea of an active pharmaceutical ingredient (API) being in
a solubilised state in a solid matrix carrier system has not yet been seen in the current
market according to the authors’ current knowledge. This is due to major technical issues
with liquisolid technology, which are still persisting after more than two decades. Such
drawbacks include issues with flow property, compressibility and inability to exist as a rea-
sonably sized dosage form when high-dose formulation is required [7–10]. In terms of flow
property, the incorporation of liquid medication in dry powder excipients is problematic
because it makes the powder cohesive, giving rise to issue concerning flowability. This in
turn creates an issue with attaining uniform feed and reproducible filling [11], which is a
major concern when considering large-scale production. High-dose drug typically needs
more liquid vehicle, which in turns need more excipients powder to improve formulation
flowability. However, this would result in an end product being too large for actual use in
patients. With the development of Liqui-Mass technology, such an issue is resolved, leading
to a presumption that Liqui-Pellet and Liqui-Tablet are highly feasible in a commercial
sense [2–6].
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Since Liqui-Mass technology is new, there may be initial confusion about whether
Liqui-Mass and liquisolid technologies are the same, as shown in the commentary by
Pezzini et al. [12]. Lam et al. [13] responded to this commentary by explaining in detail
the differences. In brief, Liqui-Pellet and liquisolid technologies share some similarities,
but there are crucial differences separating them. Both contain API that is solubilised in a
liquid vehicle and incorporated into carrier and coating material; however, the admixture
for liquisolid formulation is under liquisolid system, which is an extensively used and
defined term in liquisolid technology. The term “liquisolid systems” refers to powdered
forms of liquid medications formulated by converting liquid lipophilic drugs, or drug
suspensions or solutions of water-insoluble solid drugs in suitable non-volatile solvent
systems, into “dry” (i.e., dry-looking), nonadherent, free-flowing and readily compressible
powder admixtures by blending with a selected carrier and coating materials [14]. Notice
such a system is a dry-looking and free-flowable powder admixture. Liqui-Pellet cannot
be described as a liquisolid formulation, as it does not fall under the liquisolid system.
The API and excipients admixture are not dry-looking and nonadherent but are in fact in
a form of wet mass even before incorporating granulating liquid, which will eventually
get removed via evaporation. Such a system is termed a Liqui-Mass system. This crucial
difference between liquisolid technology and Liqui-Mass technology makes Liqui-Pellets
and Liqui-Tablets much more versatile with a high liquid load factor and having remarkable
dissolution profile, but most importantly, makes them feasible in a commercial sense.
Currently, the Liqui-Mass technology has only been employed to enhance the dis-
solution of poorly water-soluble drugs [2–6], and a prolonged-release formulation is yet
to be explored. This investigation aimed to produce a prolonged-release Liqui-Tablet for
the first time. On looking at the classical liquisolid technology, there are limited studies
on sustained-release liquisolid formulation. It seems that the concept of solubilised API
in solid powder admixture can hold some key advantages, notably the zero-order drug
release kinetic [15–17]. Zero-order release kinetic can be considered very useful in sus-
tained release formulation in terms of clinical aspect, safety and predictability in regard
to pharmacokinetics.
The prolonged-release formulation is a growing area of research due to the benefits it
can offer to patients, healthcare staff and pharmaceutical companies. It offers a more robust
and consistent drug release than conventional pills, which means better control of drug
plasma level. The sustained-release formulation can also aid patient compliance, reduce the
burden on healthcare professionals and can possibly extend the product’s patent life [18,19].
Therefore, there is an incentive to explore prolonged-release oral dosage forms using Liqui-
Mass technology. Propranolol hydrochloride is a non-selective beta-adrenergic receptor
antagonist that is widely used for treating hypertension and arrhythmias [20]. It was the
chosen API in this study to investigate the feasibility of producing a prolong-release Liqui-
Tablet. Propranolol has a short half-life of around 3 h and good permeability and solubility
(BCS Class 1), thus making it a suitable drug model for sustained-release formulations. An
API with good water solubility is a good candidate for a sustained-release formulation.
Although Liqui-Mass technology has only been applied to enhance drug release, it is
inherently suitable for sustained release. The microcrystalline cellulose (MCC), which is
the gold standard diluent for making pellets via the extrusion-spheronization method, is
known to be virtually non-disintegrating and suitable for sustained drug release [21].
The investigation aimed to produce a sustained release propranolol Liqui-Tablet through
utilizing the non-disintegrating MCC-based pellets, retarding agent (Eudragits RS PO) and
liquid vehicles. This sustained-release Liqui-Tablet used a matrix system approach, thus
omitting the commonly used polymeric film coating. This simplified the manufacturing
process and removed the issue of film coating rupturing on compression during the
production of the pellet-based tablet. The general structure of sustained release Liqui-
Tablet can be seen in Figure 1. The non-volatile co-solvent reduced the API solubility,
and the retardant polymer was within the whole pellet structure, which was compressed
into Liqui-Tablet.
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2. Materials and Methods
2.1. Chemic ls
Propranolol hydrochloride (TCI, Tokyo, Japan); Avicel PH-102 (FMC Corp., Philadel-
phia, PA, USA); Aerosil 300 (Evonik Industries AG, Hanau, Germany); propylene glycol
(Acros Organic, Fisher Scintific, Loughborough, UK); Tween 80 (Acros Organic, Fisher
Scintific, Loughborough, UK); Tween 20 (Acros, Geel, Belgium); Kolliphor EL (BASF SE,
Ludwigshafen, Germany) and Eudragit RS PO (Evonik, Essen, Germany). All other reagents
and solvent were of analytical grades.
2.2. Saturation Solubility Test
The liquid vehicles used in the saturation solubility tests of propranolol hydrochloride
were Tween 80, Tween 20 and Kolliphor EL. A saturation solubility test of propranolol
hydrochloride in deionised water was also carried out. The liquid vehicles were chosen
based on the Javadzadeh et al. study [17], where they made sustained release liquisolid
formulations containing propranolol hydrochloride. The test was prepared by adding
propranolol hydrochloride in excess in a vial containing 10 mL of specified liquid, which
was subjected to a constant condition of 37 ◦C and shaking agitation speed of 40 rpm for
24 h in a bath shaker. The filtration of the supernatant was carried out through a pre-heated
filter of pore size 0.22 µm (Merck Millipore Ltd., Carrigtwohill, Ireland), which was then
diluted with deionised water and analysed using a UV/ vis spectrophotometer (Biowave II,
Biochrom Ltd., Cambrige, UK) at a wavelength of 288 nm. The absorbance obtained was
used to determine the concentration of propranolol hydrochloride. Each test was carried
out in triplicates and the mean and standard deviation are reported.
2.3. Production of Propranolol Liqui-Tablet
The Liqui-Tablet formulations were made by compacting Liqui-Pellets under specified
compression force using a manual tablet press machine (Compaction model MTCM-I,
Globe Pharma, N w Brunswick, NJ, USA) to produce a standard convex tablet with a
diamete of 10 mm. All Liqui-Pellet formulations were produced in this manner, with
variation in the parameter such as type of liquid vehicle, the amou t of liquid ve icle,
water content, the presence or absence of the retarding agent (Eudragit RS PO) and ratio of
a binary mixture of carriers, as shown in Table 1. Propranolol hydrochloride was mixed
in a specified non-volatile co-solvent using a pestle and mortar. This liquid medication
was then blended into a specified carrier or binary carrier material. The mixture of liquid
medication and carrier was blended for 2 min at a constant rate of 125 rpm (Caleva
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Multitab, Caleva Process Solutions Ltd., Dorset, UK). A specified amount of deionized
water, which acted as a granulating liquid, was incorporated slowly into the admixture to
achieve an acceptable rheological property for extrusion (Caleva Multitab, Caleva Process
Solutions Ltd., Dorset, UK). The admixture with water was blended for 5 min, then Aerosil
300 (coating material) was added and further blended for another 5 min before extrusion.
After the specified sample was extruded, the extrudates were spheronized at an almost
constant rotation at 4000 rpm. This spheronization process was reduced to 2000 rpm if the
extrudate was likely to agglomerate. The spheronization time varied depending on the
extrudates’ plastic property to avoid agglomeration. The spheroids were then left to dry
overnight using an oven set at a constant temperature of 40 ◦C.
In order to compare the performance of tablets made from Liqui-Pellets with physical
mixture counterpart formulations, a physical mixture tablet was prepared in a similar
manner as the Liqui-Tablet but with liquid vehicle omitted. All formulations’ carrier-to-
coating-material ratios were kept constant at 20:1.
2.4. Flowability Test on Pre-Compressed Formulations
All pre-compressed tablet formulations in the form of pellets were subjected to various
flow property tests. The flow property tests included the typical angle of repose, Carr’s
compressibility index and a simple flow rate test where samples were let to flow through an
orifice, and mass per second was recorded. These tests were done in triplicates to increase
data reliability.
2.5. Particle Size Analysis Using the Sieve Method
The size distribution of pre-compressed pellets was determined using the mechanical
shaker and sieve method (Test sieve, Retsch, Haan, Germany). Each formulation of weight
around 5 g was subjected to the mechanical shaker and sieve particle size analysis with an
amplitude of 50 for 1 min and an amplitude of 40 for a further 9 min. The higher amplitude
was only used to speed up the initial sieving process but could cause damage to the pellets;
therefore, the remaining sieving process was at a lower amplitude. The size of the sieve
used was 2000, 1000, 850, 500 and 250 µm sieves. The pellets yield in these sieves were
then determined and calculated as the percentage of total pellet weight.
2.6. Friability and Tablet Hardness Test
All formulations in tablet form were subjected to a friability test. Ten tablets for each
formulation were placed in a friabilator (D-63150, Erweka, Langen, Germany), which
rotated for 4 min at a constant rate of 25 rpm. Samples that showed fracture or had a
percentage weight loss of more than 1% were considered not robust enough and thus failed
the test.
Tablet hardness test was carried out on each formulation using the tablet hardness
tester (TBH 125, Erweka, Germany). In this test, the amount of force (in Newton) required to
fracture the tablet was recorded. This was tested on 3 tablets made from each formulation,
and the mean was calculated.
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PMT-1 * — — — 22.3 180 9 — 1000 269
PMT-2 ** — — — 14.9 135 9 45 1400 269
F-1 Tween 80 12.94 0.67 12.9 180 9 — 1400 309
F-2 Tween 20 12.94 0.67 12.9 180 9 — 1400 309
F-3 Kolliphor EL 12.94 0.67 12.9 180 9 — 1400 309
F-4 Tween 20 18.24 0.78 12.2 180 9 — 1400 329
F-5 Tween 20 22.92 0.89 11.5 180 9 — 1400 349
F-6 Tween 20 18.24 0.78 9.7 135 9 45 1400 329
F-7 Tween 20 18.24 0.78 4.86 90 9 90 1400 329
F-8 Tween 20 18.24 0.78 3.0 45 9 135 1400 329
Note all formulations contain 80 mg of propranolol HCl; water was used as pre-extrusion liquid, and the carrier to coating material was at a ratio of 20:1. * PMT-1, Physical mixture tablet without Eudragit RS PO.
** PMT-2, Physical mixture tablet with Eudragit RS PO.
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2.7. In Vitro Drug Release Test
Each Liqui-Tablet and physical mixture tablet formulations contained 80 mg of pro-
pranolol hydrochloride. These tablets were subjected to a dissolution test in accordance
with the USP paddle method (708-DS Dissolution Apparatus and Cary 60 UV-Vis, Agilent
Technologies, Santa Clara, CA, USA) at 50 rpm as recommended in the FDA draft guidance
on propranolol hydrochloride [22]. The tablets were placed in the dissolution medium
containing hydrochloric acid buffer solution of pH 1.2 for 2 h, followed by changing the pH
of the dissolution medium from 1.2 to 7.4 by adding concentrated phosphate buffer solution
(for 22 h). The pH 1.2 and 7.4 simulated gastric fluid and intestinal fluid (without enzymes),
respectively. The temperature of the dissolution medium was kept constant at 37.3 ± 0.5 ◦C.
The absorbance readings were taken at a wavelength of 288 nm at a time interval of 15 min
unitl 2 h, then every 2 h until 24 h. This wavelength accords with the reference used in
Clarke’s Analysis of Drugs and Poisons [23] and published articles [17,24], which also state
that there is no shift in absorbance at 288 nm in acidic or alkaline conditions.
2.8. Dissolution Profile Comparison via Model-Independent Analysis
Where possible, Equation (1) (difference factor, f 1) and Equation (2) (similarity factor, f 2)
were used to compare the dissolution profile of different formulations [25]. Both equations
have been recommended by the US FDA (Food and Drug Administration) [26] and are
implemented by the FDA in various guidance documents [27,28]. An f 1 value between 0–15
and f 2 value between 50–100 implies the equivalence of the two dissolution profiles [29].
Details of the equations can be found in various reports in the literature [26,30–32]. In
general, in the following equations, n represents the number of dissolution sample times
and Rt (reference) and Tt (test) represent the mean percentage of drug dissolved at each
time point (t).
f 1 = {[Σt = 1n|Rt − Tt |]/[Σt = 1n Rt]} 100 (1)
f 2 = 50 log {[1 + (1/n) Σt = 1n (Rt − Tt)2]−0.5 100} (2)
2.9. Kinetic Model Analysis of Drug Release
The drug release data obtained for each formulation were applied to different drug
release kinetics models. The mathematical models that were used included zero-order,
first-order, Higuchi and Korsmeyer–Peppas model. A zero-order release model describes
a system where a drug release rate is constant in such a way that it is independent of its
concentration [33,34]. The data from the cumulative drug release can be plotted against
time [33–35]. A first-order release model describes a system where a drug release rate
is dependent on its concentration and can be obtained by plotting logarithm percentage
release of remaining drug vs the time [33,34]. The Higuchi model suggests that drug
release from an insoluble matrix is directly proportional to the square root of time and is
based on Fick’s law of diffusion. The plot of cumulative percentage of drug release against
the square root of time should be linear if drug release is a controlled release [36]. By
using the Korsemeyer–Peppas mathematical model, it is possible to study the drug release
mechanism using the n value, which is the diffusional exponent or drug release exponent.
The most appropriate kinetic model for a formulation is based on the highest square of
correlation coefficient represented as R2 value and the lowest mean percentage error [34].
3. Results and Discussion
3.1. Saturation Solubility Test
The data from the saturation solubility test in Table 2 clearly show that propranolol
hydrochloride is less soluble in non-volatile liquid vehicle than in water (~29 mg/mL). The
solubility of propranolol in Tween 80 (1.89 mg/mL), Tween 20 (1.86 mg/mL) and Kolliphor
EL (1.32 mg/mL) are very similar. In a study by Javadzadeh et al. [17], other liquid vehicles
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such as propylene glycol, PEG 400, PEG 200 and glycerine were used; however, the results
showed propranolol hydrochloride had the lowest solubility in Tween 80.
Table 2. Solubility of propranolol hydrochloride in various solvents at 37 ◦C (n = 3).
Solvent Mean Concentration(mg/mL) ± SD a
Tween 80 1.89 ± 0.01
Tween 20 1.86 ± 0.00
Kolliphor EL 1.32 ± 0.00
Water 29.03 ± 0.12
a For the composition of each formulation refer to Table 1.
3.2. Production of Propranolol Liqui-Tablet
All formulations were successfully made into Liqui-Tablet, indicating that it is possible
to incorporate Eudragit RS PO into the Liqui-Mass system to produce pellets via extrusion-
spheronization. In addition, these pellets can be compressed into tablet dosage form, pro-
ducing Liqui-Tablet. It was observed that by increasing the amount of Eudragit RS PO there
is less amount of granulating liquid (deionised water) required to produce the pellets, as
shown in Table 1. This is evident through formulation F-6 (13.7% Eudragit RS PO per dosage
form) requiring more than 3 times the granulating liquid as F-8 (41% Eudragit RS PO per
dosage form) to successfully produce pellets.
3.3. Flowability Test on Pre-Compressed Propranolol Liqui-Tablet
There is no issue regarding the flow property of all pre-compressed Liqui-Tablet
formulations as shown in Table 3. The inference from the angle of repose shows excellent
flowability for all formulations, and the inference from Carr’s compressibility index shows
mainly good flowability. This is ideal in terms of smooth commercial manufacturing
and quality control test, such as the content uniformity test. The smooth flow has been
observed in other studies on Liqui-Mass technology [2–6]; therefore, it is claimed that
Liqui-Mass technology has overcome the poor flowability problem that is seen extensively
in liquisolid technology.
3.4. Particle Size Analysis Using the Sieve Method
Data from particle size analysis in Figure 2 show that all pre-compressed Liqui-Tablet
formulations have a narrow size distribution. All pre-compressed Liqui-Tablet fall mainly
under 1000 µm sieve, whereas physical mixture is mainly under 850 µm sieve. The data
seem to show that the presence of liquid vehicle may be contributing to the increased pellet
size. Perhaps the cohesive force due to wet liquid vehicle or the increase in the plastic
property of extrudate influences the pellet size during the spheronization process.
3.5. Tablet Friability and Hardness Test
All formulations passed the friability test except for the physical mixture tablets and
F-5 (Table 4). Formulation F-5 has the highest amount of liquid vehicle, which may have
contributed to its reduction in robustness; hence, F-5 fractured. Other than formulation
F-5, all Liqui-Tablet formulations show good robustness, which is essential for potential
upscale production.
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Table 3. Flow rate (g/sec), angle of repose and Carr’s compressible index (CI%) of all formulations (n = 3).








PMT-1 6.86 ± 0.31 24.48 ± 1.17 16.17 ± 0.00 Excellentflowability Fair flowability
PMT-2 8.31 ± 0.43 21.77 ± 0.21 14.26 ± 0.00 Excellentflowability Good flowability
F-1 8.50 ± 0.14 20.77 ± 0.14 12.56 ± 2.06 Excellentflowability Good flowability
F-2 8.17 ± 0.35 22.94 ± 0.65 13.53 ± 0.00 Excellentflowability Good flowability
F-3 7.86 ± 0.33 22.79 ± 0.81 12.50 ± 0.00 Excellentflowability Good flowability
F-4 6.50 ± 0.03 26.82 ± 0.88 13.86 ± 0.00 Excellentflowability Good flowability
F-5 6.80 ± 0.32 23.39 ± 0.39 6.47 ± 0.00 Excellentflowability
Excellent
flowability
F-6 6.44 ± 0.13 24.84 ± 1.14 12.79 ± 0.00 Excellentflowability Good flowability
F-7 7.28 ± 0.21 24.11 ± 0.88 12.26 ± 0.00 Excellentflowability Good flowability
F-8 7.04 ± 0.144 24.51 ± 0.74 11.84 ± 0.00 Excellentflowability Good flowability
a For the composition of each formulation refer to Table 1. b SD, standard deviation of the mean.


































Figure 2. Particle size distribution of all formulations. 
3.5. Tablet Friability and Hardness Test 
All formulations passed the friability test except for the physical mixture tablets and 
F-5 (Table 4). Formulation F-5 has the highest amount of liquid vehicle, which may have 
contributed to its reduction in robustness; hence, F-5 fractured. Other than formulation F-
5, all Liqui-Tablet formulations show good robustness, which is essential for potential up-
scale production. 
Table 4. Friability and tablet hardness test results of all formulations. 
Formulation  % Weight Loss Fractured (Yes/No) Passed/Failed Mean Hardness ± SD a (N) 
PMT-1 --- Yes Failed 17.67 ± 2.52 
PMT-2 --- Yes Failed 22.00 ± 3.61 
F-1 0.00 No Passed 103.00 ± 10.54 
F-2 0.00 No Passed 106.00 ± 3.61 
F-3 0.08 No Passed 111.33 ± 12.70 
F-4 0.00 No Passed 102.67 ± 6.43 
F-5 --- Yes  Failed 95.67 ± 17.62 
F-6 0.00 No Passed 99.67 ± 10.02 
F-7 0.00 No Passed 69.33 ± 5.03 
F-8 0.00 No Passed 85.67 ± 4.04 
a SD, standard deviation of the mean. 
It was observed that weight loss was negligible for most Liqui-Tablet formulations. 
The liquid vehicle could be increasing the Liqui-Tablet plasticity due to the plasticising 
effect, which can increase pellet resistance to friability. 
In terms of the data obtained from tablet hardness test (Table 4), liquid vehicle does 
not have negative impact but instead increased the compactability of Liqui-Tablet, which 
can be considered a major advantage. It can be generally seen that Liqui-Tablet, which 
contains liquid vehicle, is about 5 times harder than its corresponding physical mixture 
tablet. The t-test show that all Liqui-Tablet formulations have a significantly higher hard-
ness than the physical mixture tablet (p < 0.05). This shows that liquid vehicle can in fact 
improve the tablet harndess. 
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Table 4. Friability and tablet hardness test results of all formulations.
Formulation % Weight Loss Fractured (Yes/No) Passed/Failed Mean Hardness ± SD a (N)
PMT-1 — Yes Failed 17.67 ± 2.52
PMT-2 — Yes Failed 22.00 ± 3.61
F-1 0.00 No Passed 103.00 ± 10.54
F-2 0.00 No Passed 106.00 ± 3.61
F-3 0.08 No Passed 111.33 ± 12.70
F-4 0.00 No Passed 102.67 ± 6.43
F-5 — Yes Failed 95.67 ± 17.62
F-6 0.00 No Passed 99.67 ± 10.02
F-7 0.00 No Passed 69.33 ± 5.03
F-8 0.00 No Passed 85.67 ± 4.04
a SD, standard deviation of the mean.
It was observed that weight loss was negligible for most Liqui-Tablet formulations.
The liquid vehicle could be increasing the Liqui-Tablet plasticity due to the plasticising
effect, which can increase pellet resistance to friability.
In terms of the data obtained from tablet hardness test (Table 4), liquid vehicle does not
have negative impact but instead increased the compactability of Liqui-Tablet, which can
be considered a major advantage. It can be generally seen that Liqui-Tablet, which contains
liquid vehicle, is about 5 times harder than its corresponding physical mixture tablet. The
t-test show that all Liqui-Tablet formulations have a significantly higher hardness than the
physical mixture tablet (p < 0.05). This shows that liquid vehicle can in fact improve the
tablet harndess.
3.6. In Vitro Drug Release Test
Propranolol hydrochloride sustained-release matrix-based Liqui-Tablet was success-
fully produced with good extended-release, as shown in formulation F-8 in Figure 3.
Formulation F-8 reached around 100% drug release after about 24 h. Such a result is
ideal for a sustained-release oral dosage form since extended-release drugs are typically
designed to be taken once a day by patients.
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All Liqui-Tablet formulations except for F-6, F-7 and F-8 showed around 100% drug
release within 2 h at pH 1.2. This is expected, as there was no Eudragit RS PO in the
formulations (F-1 to F-5) to retard the drug release rate.
When comparing the dissolution profile of the physical mixture with and without
Eudragit RS PO, they both show equivalence. This is supported by the model-independent
analysis using the similarity and difference factor. The f 1 is 3.50 and f 2 is 79.65. It was
initially assumed that PMT-2, which contains Eudragit RS PO, would show a slower
drug release rate than PMT-1 (without Eudragit RS PO); however, the result shows no
differences. This suggests that propranolol hydrochloride solubility could have rendered
the Eudragit RS PO retarding effect to be less effective. It should also be noted that due to
fast drug release, the time point taken for this analysis was limited.
When investigating the effect of liquid vehicles on retarding drug release rate by
comparing F-1 to F-3 with PMP-1, there seems to be a significant influence. In comparing
F-1 to F-3 with PMT-1, all difference factors were above 15, and all similarity factors
were below 50, indicating these dissolution profiles were not similar and that the liquid
vehicles were slowing down the drug release rate. Studies from Javadzadeh et al. [17] also
observed that liquid vehicle (Tween 80) had a retarding effect on propranolol hydrochloride
liquisolid compact. Formulations F-1 to F-3 are identical except for the liquid vehicle used.
Formulation F-2 (containing Tween 20) had the largest f 1 and smallest f 2 (f 1 = 204 and
f 2 = 19) compared with F-1 (containing Tween 80, f 1 = 49 and f 2 = 34) and F-3 (containing
Kolliphor EL, f 1 = 23 and f 2 = 45), suggesting that Tween 20 was the most suitable choice
of liquid vehicle in this study.
The combination of liquid vehicle and Eudragit RS PO in the formulation seems to
have a synergistic retarding effect on Liqui-Tablet, which can be seen when comparing F-6
with PMP-2, where both formulations are identical except F-6 contains a liquid vehicle.
Both the liquid vehicle and retardant seem to be an essential combination for a noticeable
retarding drug release performance.
The dissolution test data show that when Eudragit RS PO was incorporated in Liqui-
Tablet and its concentration increased, the drug release rate can be retarded markedly.
Formulation F-7 (Eudragit RS PO 27.36% w/w) has a slower drug release rate than F-6
(Eudragit RS PO 13.68% w/w). F-7 starts reaching around 100% drug release after around
1320 min (or 22 h), whereas in the case of F-6, 100% drug release was reached within
360 min (or 6 h). The retarding effect increased when Eudragit RS PO concentration was
further increased from 27.26% w/w (F-7) to 41.03% w/w (F-8), where F-8 starts reaching
100% drug release after around 1440 min (or 24 h). It is worth pointing out that the
influence of retardant concentration had more impact on the drug release rate than the water
concentration, as seen when comparing F-7 and F-8. Despite the reduction of granulating
liquid, which would usually lead to faster drug release due to the high propensity of
disintegration, the increase in retardant had a more pronounced influence in reducing the
drug release rate.
Overall, liquid vehicle does seem to have some influence on dissolution rate; however,
it is the concentration of retardant that has the most noticeable effect. The best formulation
(F-8) reaches about 100% drug release after 24 h. If 100% drug release is achievable after
24 h at acidic pH, then such a result would give matrix-based sustained-release Liqui-
Tablet a similar dissolution performance as in a film-coated sustained-release propranolol
hydrochloride dosage form [37]. With current data from this investigation, Liqui-Mass
technology seems promising in delivering a sustained-release dosage.
3.7. Kinetic Model Analysis of Drug Release
The data from the in vitro dissolution test result was applied to different kinetic models
and was evaluated by the square of correlation coefficient (R2) and mean percentage error
(MPE). This is shown in Table 5, where data from the dissolution test were taken at pH 1.2
for the first 2 h then at pH 7.4 for an additional 22 h.
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PMT-1 0.923 15.60 0.997 4.49 — — — — — First-order
PMT-2 0.907 20.98 0.996 7.59 — — — — — First-order
F-1 0.982 7.87 0.940 106.86 — — — — — Zero-order
F-2 0.967 57.16 0.844 261.29 — — — — — Zero-order
F-3 0.958 16.03 0.881 131.89 — — — — — Zero-order
F-4 0.968 12.49 0.914 254.73 — — — — — Zero-order
F-5 0.969 11.82 0.702 567.20 — — — — — Zero-order
F-6 0.998 4.74 0.976 22.65 0.971 20.63 0.994 5.07 1.327 Zero-order
F-7 0.838 43.18 0.905 37.43 0.953 17.72 0.923 19.48 0.941 Higuchi
F-8 0.823 50.84 0.885 45.09 0.946 20.18 0.914 21.76 1.030 Higuchi
R2 is the square of correlation coefficient. n is the diffusional exponent or drug release exponent. MPE is the mean percentage error. — due
to fast drug release, these parameters cannot be calculated.
Since the mathematical model for the Higuchi and Korsmeyer–Peppas model are
usually only valid for the first 60 % of the drug release [38], only zero-order and first-order
models were applied to formulations with a fast drug release rate. The observation in
the dissolution profiles (Figure 3) shows that most formulations have quick drug release,
except for Liqui-Tablet with retarding agent (F-6 to F-8). Only zero-order and first-order
mathematical models were applied to the quick drug releasing formulations. The results
show that the release models for F-1 to F-5 follow the zero-order model, and the physical
mixture tablet follows first-order model. This means that in formulation F-1 to F-5, the
drug is released at a constant manner, which is beneficial in terms of maintaining a constant
drug plasma level throughout the delivery. The physical mixture tablet follows the first-
order kinetic, which means that the drug release for these formulations is dependent on
concentration. The release is proportional to the amount of propranolol hydrochloride
remaining in the dosage form; therefore, drug release diminishes over time [32]. It has been
observed in a study from Mulye and Turco [39] that water-soluble drug in porous matrices
follow the first-order model, which may suggest that the fast releasing tablets made in this
investigation may be porous matrices. It is interesting that Liqui-Tablet follows a zero-order
kinetic model.
When a sufficient amount of Eudragit RS PO is incorporated into Liqui-Tablet, it is
clear that the kinetic model changes. The addition of the retarding agent at a concentration
of 27.4% (F-7) and 41% (F-8) show the highest R2 value for the Higuchi model in Table 5
(R2 = 0.953 with MPE of 17.72, and R2 = 0.946 with MPE of 20.18, respectively). Based on
the data from the Higuchi model, it can be interpreted that the key mechanism of drug
release for F-7 and F-8 is diffusion-controlled [39].
Although the F-7 and F-8 drug release kinetic is predominantly Higuchi, the Korsmeyer–
Peppas R2 values are equal to or above 0.914, and so there may be several release mech-
anisms involved. The n value for Korsmayer–Peppas in F-7 (n = 0.941) suggests case II
transport and zero-order release [39]. Case II transport is considered to be an anomalous
diffusion phenomenon that does not accord with Fick’s equation [40]. It is controlled by
the swelling and relaxation of the drug delivery system matrix and is independent of time.
As for F-8, the n value above 1 suggests super case II. This describes the influence of water
uptake and swelling on the drug release for the polymeric and swellable system.
4. Conclusions
The study confirms that it is possible to produce an effective sustained release Liqui-
Tablet using Eudragit RS PO within the matrix of the dosage form. The drug release of
propranolol hydrochloride Liqui-Tablet was able to be sustained, with drug release reaching
around 100% after about 24 h. The physical mixture tablet with Eudragit RS PO retarding
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agent did not have a very noticeable influence on retarding drug release. Liquid vehicles
did display an influence on retarding drug release; however, when they were combined
with Eudragit RS PO, there seems to be an obvious synergistic retarding effect, which can
be effective at certain retardant concentrations. This suggests that Liqui-Mass technology
may be an effective solution for producing sustained-release dosage in a simplistic and
cost-effective manner. The drug release of the best formulation follows a Higuchi model,
indicating a diffusion-controlled drug release. It was also found that liquid vehicle can sig-
nificantly improve tablet hardness. In terms of pre-compressed Liqui-Tablet flow property,
particle size distribution and Liqui-Tablet robustness, there seems to be no major issue.
5. Patents
Application no. PCT/GB2019/052065 was filed on 24 July 2019 and published inter-
nationally on 30 January 2020 (International Publication Number WO2020/021254 A1).
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